PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study-Reference-Cited by-同舟云学术

PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study

Published:2020-05-05 Issue:4 Volume:26 Page:2225-2235
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Beer Andrea,Taghizadeh Hossein,Schiefer Ana-Iris,Puhr Hannah C.,Karner Alexander K.,Jomrich Gerd,Schoppmann Sebastian F.,Kain Renate,Preusser Matthias,Ilhan-Mutlu Aysegül^ORCID

Funder

Medizinische Universität Wien

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12253-020-00814-2.pdf

Reference36 articles.

1. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, Committee EG (2016) Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v38–v49. https://doi.org/10.1093/annonc/mdw350

2. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202–209. https://doi.org/10.1038/nature13480

3. Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM, Kang WK, Kim S, Kim KM (2017) Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget 8 (8):13320-13328. https://doi.org/10.18632/oncotarget.14519

4. Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, Tan P, Roviello F (2017) Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg 105:159–167. https://doi.org/10.1002/bjs.10663

5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three biomarkers (HER2, PD‐L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience;International Journal of Cancer;2024-07-12

2. HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches;Cancers;2024-03-20

3. Brain Tumor Detection Based on Deep Learning Approaches and Magnetic Resonance Imaging;Cancers;2023-08-18

4. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers;Cancers;2023-08-14

5. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies;International Journal of Molecular Sciences;2023-07-13